CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 23 enrolled
Drug / intervention
F-18 florbetapir PETdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01683825
NCT01683825Phase 4Completed
CompareCT.gov

Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography

Brigham and Women's Hospital·interventional·Posted Sep 12, 2012·Updated Nov 20, 2025

In Brief

A Phase 4 clinical trial evaluating F-18 florbetapir PET for Cardiac Amyloidosis. Completed, enrolled 23 participants across 1 site.

Detailed Summary

The primary aim of this pilot study is to determine whether amyloid deposits in the heart can be measured non-invasively by F-18 florbetapir (Trade Name: Amyvid) positron emission tomography (PET) in 30 individuals with documented cardiac amyloidosis. We will also enroll 15 individuals without cardiac amyloidosis to undergo the F-18 florbetapir imaging as a control group. The primary hypothesis of this study is that a specific amyloid binding radiotracer will bind to the myocardial amyloid deposits and help quantify cardiac amyloid burden. A secondary aim of this study is to determine reproducibility of F-18 florbetapir imaging of the myocardium.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiac Amyloidosis
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 12, 2012
Enrollment StartMar 23, 2013
Primary CompletionOct 4, 2018
Study CompletionOct 10, 2018
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 13.8 years ago

Interventions

F-18 florbetapir PETdrug

Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid)